Debio 1347 was firstly evaluated in a first-in-human trial on advanced solid tumors, reporting a safety profile acceptable up to 80 mg daily (NCT01948297) [80]; this study evaluated Debio 1347 in 18 patients, including five cases of CCA (four patients with FGFR2 fusion and one case of FGFR1 fusion). The gene discussed is FGFR1; the disease is cholangiocarcinoma.